About us

We are a global leaders in medicinal cannabis, committed to quality, innovation and caring for patients around the world.

Linneo in Figures


Meet our leadership team


Don Bellamy

Chief Executive Officer

With a career spanning 30 years, Don has held several positions within the pharmaceutical and regulated cannabis industries prior to becoming CEO at Linneo Health.
Don was previously Senior Vice President for Global Medical Products at Canopy Growth in Canada, where he was responsible for the global strategic and operational development of Spectrum Cannabis and Canopy’s medical prescription business. He also founded the life sciences and medical cannabis consulting firm, Goodfriend Consulting.
Don started his career in the pharmaceutical sector, where he held several positions of increasing responsibility in Baxalta-Shire, Novartis and AstraZeneca. He has extensive experience in global roles, general management, marketing, and business operations. As Global Head of Marketing and Launch Excellence at Baxalta-Shire, he implemented a standardized launch process for the company, estimated to have added $1bn in topline sales.
He brings extensive therapeutical expertise in disease areas such as pain, oncology, and neurological conditions, and has built up an extensive business and regulatory network across the world.


Gerardo Gorostiza

Chief Financial Officer

Gerardo received degrees in Industrial Engineering in Business Administration and MBA from IE Business School. He has extensive experience in financial management and M&A, having successfully held management positions in various multinational companies (Uralita, Adveo or the Costa Food Group) and started his career as a consultant at PwC. His background supports his position to establish financial health and secure appropriate resources with a vision for future growth for Linneo.


Mª Ángeles Muñoz

Quality & Regulatory
Affairs Director

María Ángeles has more than 20 years of experience in multinationals, small companies (including Novartis, Telstar and Pharmex) and consulting for the pharmaceutical industry, having held various roles related to regulatory strategy and chemical-pharmaceutical documentation at a national and international level. She is greatly knowledgeable about the life cycle of medicines, food supplements, health products and cosmetics, with relevant experience in positions and departments including Director of Consulting, Regulatory Affairs, the departments of Quality, Audits, Validations, Medical Affairs and Pharmacovigilance.


Sergio Moreno


As the Production Director at Linneo Health, Sergio leads a team that ensuring Linneo´s production is in full compliance with GACP and EU-GMP standards. He also oversees Linneo’s search, selection, testing, and licensing of new genetics used in the process. Sergio holds a degree in Agricultural Engineering and has accumulated over 25 years of experience in the industry, working in The Netherlands, Mexico, and Spain.
Sergio is experienced in the successful launch and management of advanced and highly intensive facilities for the manufacturing of high-value products, from agri-food and ornamental to medicinal sectors. At Linneo Health, he has successfully implemented essential infrastructure and facility improvements to enable the cultivation and processing of high-quality products in a safe and efficient environment.
Sergio’s previous roles include COO of Aleia Roses, a sustainable greenhouse operation spanning 14 hectares. For almost 13 years, served as the Director of Technical Operations of Bionatur, the largest hi-tech greenhouse operation in Mexico, covering 85 hectares.

Our history

Linneo Health is a global leader in the research, EU-GMP certified manufacture and supply of medicinal cannabis flowers, extracts and products to pharmaceutical partners developing innovative cannabis-based therapies for patients in need. As the world’s only vertically integrated medicinal cannabis supplier, supported by 90 years of unparalleled heritage and experience in the production of strictly regulated pharmaceutical products, Linneo Health is setting the benchmark for quality in research, cultivation and supply of medicinal cannabis to drive innovation and excellence in the field.


Linneo’s European operations center in Southern Spain is optimally positioned to address the needs of its customers through every stage of product development, regulation and handling. Driven by the belief that people around the world deserve to be treated with cannabis medicine of the highest standard, Linneo’s expertise provides a clear reference for today’s industry, alongside significant expansion capabilities to support the development of tomorrow’s solutions in a rapidly evolving market.

Linneo Health takes 90 years of experience in the agricultural and industrial production of highly regulated narcotics and puts them at the service of the cannabis industry. We work with the highest production standards, and this clear focus on the quality of what we do has been accredited by the EU-GMP and GACP certifications to our production process.

With an ambitious expansion plan, we currently have an installed capacity of 40,000 m2 dedicated to cannabis flowers. In addition, we have an industrial capacity to process more than 12,000 tonnes of plant material per year, destined for the production of extracts and active ingredients derived from cannabis. All this positions us as market leaders and a clear reference in the sector.


Linneo Health was created to provide the highest quality medical cannabis products to improve lives.


We aim to improve the lives of patients by providing the highest quality medical cannabis products to our partners. To achieve this, we work with pharmaceutical and medical groups to whom we supply the product that best suits the needs of their patients.


Advancing medical cannabis research and technology
Our cannabis variety research and agricultural techniques that benefit patients who need this product is paramount to our operation. Our team of scientists and engineers is at the forefront of innovation, driving the latest technological advances in the field of medicinal cannabis. We strive to constantly offer the latest in this field.


Choosing partners who trust in our comprehensive experience
Our partners choose us because of our comprehensive experience in all aspects of medical cannabis production. From cultivation, production and processing of a product of consistent quality, the management and compliance with complex legal and regulatory requirements, to its handling and transportation, we provide everything our customers need.


Working together from seed to success
As the only vertically integrated provider offering a full service to our clients, we are committed to working hand-in-hand with them at every stage, from seed to success. We exceed industry best practices in every phase of production, applying rigorous interpretations of the highest standards in the world and are committed to growing with our partners to meet the changing needs of medicinal cannabis globally.


Treating patients with the best medical cannabis
We firmly believe that all patients deserve to be supplied with the best medicinal cannabis. Our unwavering focus on quality is the foundation of our business, and we focus on delivering quality in medicinal cannabis research, cultivation and supply.

Linneo's Milestones

September 2023
Italy Launch. Commercial entry in Italy following award of exclusive contract by the Italian government., becoming only company currently supplying medicinal cannabis to the government of Italy.
April 2023
Obtained the CUMCS Equivalency IMC-GAP certification, supporting the Company's challenging expansion plan.
September 2022
Dried flower facility awarded the EU-GMP Part I license by the (AEMPS), for the manufacture of intermediates and finished medicinal cannabis products. This new certification greatly extends our existing Part II license for the manufacture of Active Pharmaceutical Ingredients (APIs).
July 2022
Awarded maximum grant of €200,000 from the ICEX, Invest in Spain framework, to support our ongoing CANNABI+ project, which aims to develop new cannabis varieties with unique cannabinoid and terpene profiles. Expanded our medicinal cannabis offering to include industrial derivatives, following the issuance of EU-GMP certification for the industrial processing of cannabis derivatives to Alcaliber, by the (AEMPS).
September 2021
Obtained GMP Certification for our newly built quality control laboratory by the (AEMPS) and renewed existing GMP certification for the current facility, allowing us to continue being a leader in the cannabis sector.
April 2021
State-of-the-art Quality Control Laboratory became fully operational and received GLP certification by the (AEMPS) for GLP certification.
Shipped the first commercial products to our client, officially starting our commercial journey. Satisfactory approval achieved for dossier of irradiated product for Germany. Launch of first commercial batch in Germany. Harvest of largest cannabis outdoor crop destined for export. Completion of dedicated cannabis extraction unit.
December 2019
Cultivation area awarded with the Good Agricultural and Collection Practices (GACP) certificate, which restates our cultivation process as the reference in the medicinal cannabis sector.
September 2019
Received the Good Manufacturing Practices (GMP) quality certificate from the Spanish Agency for Medicines and Health Devices (AEMPS) - the first Spanish cannabis company to receive this certification.
Juny 2019
First outdoor growing area approved, significantly expanding our agricultural capacity and strengthening our robust business model.
Started construction on first greenhouse for growing our medicinal cannabis.
October 2016
Received authorization for the cultivation of cannabis with medicinal and scientific purposes from the Spanish Agency for Medicines and Health Devices (AEMPS).
Scroll to Top